Major Blue Chip Analyst Upgrades and Downgrades in Apple, Intel, Caterpillar, Gilead, JPMorgan and Nike
These are the top 24/7 Wall St. blue chip upgrades, downgrades and initiations tracked for the week of September 9.
These are the top 24/7 Wall St. blue chip upgrades, downgrades and initiations tracked for the week of September 9.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Biogen, Broadcom, Devon Energy, Gilead Sciences, Mondelez and Urban Outfitters.
September 2, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Friday’s session. NYSE advancers led decliners by nearly 4 to 1 and…
September 1, 2016: Here are four stocks trading with relatively heavy volume among 39 equities making new 52-week lows in Thursday’s session. NYSE decliners led advancers by about 5 to 4 and…
August 31, 2016: Here are four stocks trading with relatively heavy volume among 27 equities making new 52-week lows in Wednesday’s session. NYSE decliners led advancers by 3 to 2 and Nasdaq…
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Abercrombie & Fitch, Alibaba, Baidu, First Data, Marvell Technology and Under Armour.
August 29, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Monday’s session. NYSE advancers led decliners by about 7 to 3 and…
The August 15 short interest data have been compared with the previous report, and short interest moves were mixed across these selected biotech stocks.
Medivation has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, nor do we know what…
Investors are now focusing on fundamentals and near-term catalysts that could provide a tailwind for some of the biotech leaders.
The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech stocks.
Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there was little to no mention of drug pricing.
Gilead Sciences reported its earnings on Monday of last week, and since that time there has been much analyst activity around the stock.
The recent performance from Gilead Sciences has analysts and investors concerned about the future. Argus believes that the headwinds are blowing harder than the tailwinds for the company.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Alphabet, Amazon, Dow Chemical, Ford, Gilead, Harley-Davidson and Western Digital.